COMP <GO>
BIVI vs KTTA // 10Y YIELD & FRED MACRO BETA
BioVie Inc. (Class A) (NASDAQ) VS. Pasithea Therapeutics Corp. (NASDAQ) • 15-METRIC TALLY: BIVI 2
— KTTA 0
■ METRIC PARITY
LAST: $1.37 (-4.20%) • MKT CAP: $12.4M
macro-sensitivity
—
LAST: $0.37 (-0.59%) • MKT CAP: $12.4M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIVI VS. KTTA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIVI | KTTA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.2 | 34.2 | +17.00 | BIVI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.4M | $12.4M | $46.2K | BIVI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIVI REV | KTTA REV | BIVI GROSS % | KTTA GROSS % | BIVI FCF | KTTA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $50.6M | $58.4M | — | — | -$19.0M | -$15.2M |
| FY 2024 | $90.1M | $39.9M | — | — | -$27.9M | -$13.9M |
| FY 2023 | $126.2M | $44.7M | — | — | -$40.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIVI // BETA —
KTTA // BETA —